Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $4.34 million. The enterprise value is -$6.40 million.
| Market Cap | 4.34M |
| Enterprise Value | -6.40M |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 3.98 million shares outstanding. The number of shares has increased by 2,741.23% in one year.
| Current Share Class | 3.98M |
| Shares Outstanding | 3.98M |
| Shares Change (YoY) | +2,741.23% |
| Shares Change (QoQ) | +19.38% |
| Owned by Insiders (%) | 20.74% |
| Owned by Institutions (%) | 2.35% |
| Float | 2.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.42 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.21, with a Debt / Equity ratio of 0.07.
| Current Ratio | 6.21 |
| Quick Ratio | 6.11 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -154.77% and return on invested capital (ROIC) is -96.27%.
| Return on Equity (ROE) | -154.77% |
| Return on Assets (ROA) | -78.73% |
| Return on Invested Capital (ROIC) | -96.27% |
| Return on Capital Employed (ROCE) | -106.14% |
| Weighted Average Cost of Capital (WACC) | 2.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.13M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.23% in the last 52 weeks. The beta is -0.17, so REVB's price volatility has been lower than the market average.
| Beta (5Y) | -0.17 |
| 52-Week Price Change | -89.23% |
| 50-Day Moving Average | 1.06 |
| 200-Day Moving Average | 1.88 |
| Relative Strength Index (RSI) | 50.47 |
| Average Volume (20 Days) | 32,124 |
Short Selling Information
The latest short interest is 20,729, so 0.52% of the outstanding shares have been sold short.
| Short Interest | 20,729 |
| Short Previous Month | 20,200 |
| Short % of Shares Out | 0.52% |
| Short % of Float | 0.70% |
| Short Ratio (days to cover) | 0.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.27M |
| Pretax Income | -10.75M |
| Net Income | -19.20M |
| EBITDA | -11.24M |
| EBIT | -11.27M |
| Earnings Per Share (EPS) | -$8.31 |
Balance Sheet
The company has $11.48 million in cash and $739,916 in debt, with a net cash position of $10.74 million or $2.70 per share.
| Cash & Cash Equivalents | 11.48M |
| Total Debt | 739,916 |
| Net Cash | 10.74M |
| Net Cash Per Share | $2.70 |
| Equity (Book Value) | 10.07M |
| Book Value Per Share | 2.58 |
| Working Capital | 9.80M |
Cash Flow
In the last 12 months, operating cash flow was -$9.33 million and capital expenditures -$111,507, giving a free cash flow of -$9.44 million.
| Operating Cash Flow | -9.33M |
| Capital Expenditures | -111,507 |
| Depreciation & Amortization | 28,133 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.44M |
| FCF Per Share | -$2.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
REVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,741.23% |
| Shareholder Yield | -2,741.23% |
| Earnings Yield | -442.25% |
| FCF Yield | -217.40% |
Analyst Forecast
The average price target for REVB is $17.75, which is 1,528.44% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.75 |
| Price Target Difference | 1,528.44% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 28, 2026. It was a reverse split with a ratio of 1:4.
| Last Split Date | Jan 28, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |